Joji Suzuki
Brigham and Women's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
7
all conditions, ClinicalTrials.gov
NIH grants tied to them
9
NIH RePORTER
Trial papers
75
PubMed author-name match
Trials
Studies that name Joji Suzuki as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:58 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07296094 · Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use DisorderBrigham and Women's Hospital · not yet recruiting · Alcohol Use Disorder · principal investigator
- Ph2NCT07265752 · Tirzepatide for the Treatment of Cannabis Use DisorderBrigham and Women's Hospital · not yet recruiting · Cannabis Use Disorder · principal investigator
- Ph2NCT07132177 · Targeted Naltrexone to Support Individuals Participating in Dry JanuaryBrigham and Women's Hospital · completed · Alcohol Misuse · principal investigator
- Ph2NCT06727331 · Study of Tirzepatide for Recovery and Alcohol Use ManagementBrigham and Women's Hospital · recruiting · Alcohol Use Disorder (AUD) · principal investigator
- N/ANCT04223011 · Initiating Substance Use Disorder Treatment for Hospitalized Alcohol Use Disorder PatientsBrigham and Women's Hospital · withdrawn · Alcohol Use Disorder · principal investigator
- Ph2NCT04192370 · Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on BuprenorphineBrigham and Women's Hospital · completed · Opioid-use Disorder · principal investigator
- N/ANCT03212794 · Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.Brigham and Women's Hospital · completed · Opioid-use Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Safety and preliminary efficacy of ibogaine as a treatment for opioid use disorderUG3DA064414 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2026 · $2,288,947 awarded in 2026Same name and institution; not confirmed by an ID
- Extended release buprenorphine as a novel low-dose induction strategyR21DA060411 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2024 to 2025 · $260,775 awarded in 2025Same name and institution; not confirmed by an ID
- Ketamine for the treatment for opioid use disorder and suicidal ideation in the emergency departmentR21DA058119 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2023 to 2024 · $268,500 awarded in 2024Same name and institution; not confirmed by an ID
- Oral buprenorphine as a novel low-dose induction strategy for individuals with opioid use disorderR21DA057545 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2023 to 2024 · $265,102 awarded in 2024Same name and institution; not confirmed by an ID
- Semaglutide for the treatment of opioid use disorder: A pilot randomized controlled trialR21DA060304 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2024 · $492,250 awarded in 2024Same name and institution; not confirmed by an ID
- Developing and pilot testing a novel remotely delivered intensive outpatient program for individuals with opioid use disorder hospitalized with serious injection-related infectionsR21DA056799 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2022 to 2023 · $319,323 awarded in 2023Same name and institution; not confirmed by an ID
- Ketamine for the treatment for alcohol use disorder in the emergency department: A pilot double-blind, placebo-controlled randomized clinical trialR21AA030372 · NIAAA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2022 to 2023 · $212,563 awarded in 2023Same name and institution; not confirmed by an ID
- Oral complications from sublingual buprenorphine treatment: A prospective cohort studyR21DE033319 · NIDCR · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2023 · $419,819 awarded in 2023Same name and institution; not confirmed by an ID
- Initiating substance use disorder treatment in hospitalized opioid use disorder patientsK23DA042326 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · fiscal years 2017 to 2021 · $199,800 awarded in 2021Grant number is on one of their registry trials
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:58 UTC. The ranking covers the 200 most relevant of 75 PubMed records, and a shared surname and initials can bring in a namesake. All 75 on PubMed
- The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.Aliment Pharmacol Ther · 200390 citationsRCR 2.8
- A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker.Int Heart J · 200756 citationsRCR 1.2
- Efficacy of methylprednisolone and urokinase pulse therapy combined with or without cyclophosphamide in severe Henoch-Schoenlein nephritis: a clinical and histopathological study.Nephrol Dial Transplant · 200452 citationsRCR 1.8
- Accentuated vagal antagonism of beta-adrenergic effects on ventricular repolarization. Evidence of weaker antagonism in hostile type A men.Circulation · 199250 citationsRCR 2.1
- Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long term analysis with nuclear magnetic resonance imaging.J Am Coll Cardiol · 199950 citationsRCR 1.4
- Stroke and cardio-ankle vascular stiffness index.J Stroke Cerebrovasc Dis · 201348 citationsRCR 2.0
- Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study.J Neurol Sci · 199748 citationsRCR 1.4
- 47 citationsRCR 1.8
- Long-term follow up of initial clinical cases with NF-kappaB decoy oligodeoxynucleotide transfection at the site of coronary stenting.J Gene Med · 200843 citationsRCR 1.0
- Evaluation of T helper-1/-2 balance on the basis of IgG subclasses and serum cytokines in children with glomerulonephritis.Am J Kidney Dis · 200442 citationsRCR 0.8